Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Gastrointestinal Stromal Tumors Specialty Channel

Gastrointestinal Stromal Tumors
Specialty Channel
Conference Coverage
02/24/2023
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective...
02/24/2023
Oncology
News
01/19/2023
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal...
01/19/2023
Oncology
News
12/20/2022
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study,...
12/20/2022
Oncology
News
11/17/2022
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal...
11/17/2022
Oncology
News
11/10/2022
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal...
11/10/2022
Oncology
Quiz
10/18/2022
Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.
Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.
Did ripretinib demonstrate...
10/18/2022
Oncology
News
09/27/2022
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with...
09/27/2022
Oncology
News
09/20/2022
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the...
09/20/2022
Oncology
News
08/04/2022
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative...
08/04/2022
Oncology
News
08/03/2022
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor...
08/03/2022
Oncology
News
08/03/2022
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative...
08/03/2022
Oncology

News

Conference Coverage
02/24/2023
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective...
02/24/2023
Oncology
News
01/19/2023
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal...
01/19/2023
Oncology
News
12/20/2022
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study,...
12/20/2022
Oncology
News
11/17/2022
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal...
11/17/2022
Oncology
News
11/10/2022
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal...
11/10/2022
Oncology
News
09/27/2022
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with...
09/27/2022
Oncology
News
09/20/2022
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the...
09/20/2022
Oncology
News
08/04/2022
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative...
08/04/2022
Oncology
News
08/03/2022
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor...
08/03/2022
Oncology
News
08/03/2022
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative...
08/03/2022
Oncology

Interactive Features

Quiz
10/18/2022
Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.
Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.
Did ripretinib demonstrate...
10/18/2022
Oncology
Test Your Knowledge
02/24/2022
True or false: Acknowledging GISTs are the most common sarcoma of the GI tract, with estimated incidence between 1.0 and 1.5/100,000 per year, current estimates suggest prevalence decreasing incidences. 
True or false: Acknowledging GISTs are the most common sarcoma of the GI tract, with estimated incidence between 1.0 and 1.5/100,000 per year, current estimates suggest prevalence decreasing incidences. 
True or false: Acknowledging...
02/24/2022
Oncology
Test Your Knowledge
02/18/2022
True or false: Typically, clinical trials or targeted therapies are recommended for patients with c-KIT and PDGFRA wild-type GIST who are unable to obtain multi-target protein tyrosine kinase inhibitors therapy.
True or false: Typically, clinical trials or targeted therapies are recommended for patients with c-KIT and PDGFRA wild-type GIST who are unable to obtain multi-target protein tyrosine kinase inhibitors therapy.
True or false: Typically,...
02/18/2022
Oncology
Quiz
08/11/2021
Which method is confirmed to provide better aid in the diagnosis of GIST therapy?
Which method is confirmed to provide better aid in the diagnosis of GIST therapy?
Which method is confirmed to...
08/11/2021
Oncology
Quiz
08/10/2021
True or false: In localized, high-risk GIST, patients with chromosomal complexities have poor RFS.
True or false: In localized, high-risk GIST, patients with chromosomal complexities have poor RFS.
True or false: In localized,...
08/10/2021
Oncology
Interactive Features
06/02/2021
True or False: Findings from a retrospective analysis suggest the clinical features and treatment approaches for multiple gastrointestinal stromal tumors (MGISTs) may differ from single GISTs, ultimately presenting a gap in the treatment...
True or False: Findings from a retrospective analysis suggest the clinical features and treatment approaches for multiple gastrointestinal stromal tumors (MGISTs) may differ from single GISTs, ultimately presenting a gap in the treatment...
True or False: Findings from a...
06/02/2021
Oncology
Test Your Knowledge
05/03/2021
True or False: A genetic diagnosis yields benefit in gastrointestinal stromal tumor therapy by informing the patient and provider(s) of the possibility for other malignancies, suggested surveillance, management for other NF1 comorbidities,...
True or False: A genetic diagnosis yields benefit in gastrointestinal stromal tumor therapy by informing the patient and provider(s) of the possibility for other malignancies, suggested surveillance, management for other NF1 comorbidities,...
True or False: A genetic...
05/03/2021
Oncology
Test Your Knowledge
04/07/2021
True or false: Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.
True or false: Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.
True or false: Ripretinib is a...
04/07/2021
Oncology
Test Your Knowledge
03/29/2021
True or false: Prolonged adjuvant imatinib therapy extends overall survival in patients with high-risk GIST.
True or false: Prolonged adjuvant imatinib therapy extends overall survival in patients with high-risk GIST.
True or false: Prolonged...
03/29/2021
Oncology
Test Your Knowledge
02/09/2021
Which of the following combination treatment options has yielded the best outcomes in patients with stage IV GIST?
Which of the following combination treatment options has yielded the best outcomes in patients with stage IV GIST?
Which of the following...
02/09/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement